AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20346621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pass filter cutoff frequency of 100 Hz
Number of subjects: 0
Study 20346621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pass filter cutoff frequency of 300 Hz
Number of subjects: 0
Study 19731228 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (600 mg intravenously in two divided doses, at least 24 hours apart, 14 days before surgery)
Number of subjects: 60
Study 19731228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given intravenously in two divided doses, at least 24 hours apart, 14 days before surgery)
Number of subjects: 60
Study 17679132 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 26563
Study 15559735 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based intervention to prevent skin cancer
Number of subjects: 340
Study 15559735 — intervention group
Group type: COMPARATOR
Intervention: Control group (129 children)
Number of subjects: 340
Study 11312473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% (n = 12)
Number of subjects: 22
Study 11312473 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.2 to 0.3 mg/kg (n = 10)
Number of subjects: 22
Study 9726264 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 302
Study 9726264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense outpatient treatment
Number of subjects: 302
Study 9726264 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard outpatient treatment
Number of subjects: 302
Study 9726264 — intervention group
Group type: COMPARATOR
Intervention: Decliners (control group)
Number of subjects: 302
Study 1599887 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 20 ml 0.375% bupivacaine with 1:200,000 epinephrine at a rate of 6 ml/hour during the first 24 hours postoperatively
Number of subjects: 80
Study 1599887 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of 20 ml 0.375% bupivacaine with 1:200,000 epinephrine at four-hour intervals
Number of subjects: 80
Study 3904335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 162
Study 3904335 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide
Number of subjects: 162
Study 31666259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 112
Study 31666259 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine
Number of subjects: 112
Study 31666259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tryptophan and phenylalanine
Number of subjects: 112
Study 31666259 — intervention group
Group type: COMPARATOR
Intervention: Combination of AAs
Number of subjects: 112
Study 29788136 — intervention group
Group type: EXPERIMENTAL
Intervention: FertiEduc group (fertility information)
Number of subjects: 208
Study 29788136 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy pregnancy information)
Number of subjects: 208
Study 27692842 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR 10 μg
Number of subjects: 0
Study 27692842 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR 25 μg
Number of subjects: 0
Study 27692842 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR 4 μg
Number of subjects: 0
Study 27692842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24484540 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-band RDT
Number of subjects: 1648
Study 24484540 — intervention group
Group type: COMPARATOR
Intervention: HRP2 alone
Number of subjects: 1648
Study 24484540 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 1648
Study 21721988 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine collagen matrix (PCM) plus coronally advanced flap (CAF)
Number of subjects: 18
Study 21721988 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) plus coronally advanced flap (CAF)
Number of subjects: 18
Study 19617849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 610
Study 19617849 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 610
Study 19617849 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal viral load (pre-entry)
Number of subjects: 610
Study 19617849 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count
Number of subjects: 610
Study 19617849 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal viral load (6-8 weeks)
Number of subjects: 610
Study 19617849 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal NVP resistance (6-8 weeks)
Number of subjects: 610
Study 17276786 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental training using visual demonstration of respiratory particle dispersion
Number of subjects: 20
Study 17276786 — intervention group
Group type: COMPARATOR
Intervention: Standard classroom training
Number of subjects: 20
Study 15382120 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS (transjugular intrahepatic portosystemic shunt)
Number of subjects: 116
Study 15382120 — intervention group
Group type: COMPARATOR
Intervention: HR-non-TIPS group
Number of subjects: 116
Study 11156638 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg once daily
Number of subjects: 120
Study 11156638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9685100 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (CM) 4mg
Number of subjects: 18
Study 9685100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9139377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nakayama strain JE vaccine
Number of subjects: 0
Study 9139377 — intervention group
Group type: EXPERIMENTAL
Intervention: Beijing strain JE vaccine
Number of subjects: 0
Study 2198921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride
Number of subjects: 0
Study 2198921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 352700 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 352700 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and Sotalol
Number of subjects: 0
Study 31232512 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-size family ration with individual ration of corn-soy blend or micronutrient powder in Guatemala; lowest cost per percentage point reduction in stunting.
Number of subjects: 0
Study 31232512 — intervention group
Group type: EXPERIMENTAL
Intervention: Food assistance for the full 1,000 days in Burundi; lowest cost per percentage point reduction in stunting.
Number of subjects: 0
Study 31232512 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced duration of ration eligibility in Burundi; less effective than full duration.
Number of subjects: 0
Study 31232512 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year extension of the program in Guatemala; potential savings of 11% per beneficiary.
Number of subjects: 0
Study 31232512 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year extension of the program in Burundi; potential savings of 18% per beneficiary.
Number of subjects: 0
Study 28630081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment
Number of subjects: 3883
Study 28630081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study 26188787 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial decompression with bursectomy and arthroscopic removal of calcific deposit
Number of subjects: 80
Study 26188787 — intervention group
Group type: COMPARATOR
Intervention: Bursectomy and arthroscopic removal of calcific deposit without subacromial decompression
Number of subjects: 80
Study 23183639 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine (serum target 50 ng/ml)
Number of subjects: 11
Study 23183639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23183639 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine (serum target 10 ng/ml)
Number of subjects: 11
Study 23183639 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine (serum target 30 ng/ml)
Number of subjects: 11
Study 21649623 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Risk Assessment MedGuide (GRAM) reports and automated monitoring plans for falls and delirium
Number of subjects: 1711
Study 20077901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education programme and fluoride toothpaste use under parental supervision
Number of subjects: 400
Study 20077901 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 400
Study 20077901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education programme
Number of subjects: 400
Study 16773005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal CO2 insufflation
Number of subjects: 30
Study 16773005 — intervention group
Group type: COMPARATOR
Intervention: Abdominal wall lift
Number of subjects: 30
Study 15544879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin for 5 days (long-term group)
Number of subjects: 34
Study 15544879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (short-term group)
Number of subjects: 34
Study 12536735 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocreatine (neoton) group (group CP) - 4.0 g neoton intravenously 2 days before operation
Number of subjects: 20
Study 12536735 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C) - 5% G. S instead of neoton
Number of subjects: 20
Study 9434695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia (4:1 dilution, blood/Plegisol, potassium chloride 15 mEq/L; n = 62)
Number of subjects: 138
Study 9434695 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (Plegisol; n = 76)
Number of subjects: 138
Study 9434695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 138
Study 8311290 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-midazolam-alfentanil
Number of subjects: 130
Study 8311290 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-alfentanil
Number of subjects: 130
Study 8311290 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-propofol
Number of subjects: 130
Study 8311290 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil
Number of subjects: 130
Study 2455425 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 25 mg methotrexate
Number of subjects: 23
Study 2455425 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of 25 mg methotrexate
Number of subjects: 23
Study 2455425 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance methotrexate therapy
Number of subjects: 23
Study 31839501 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin cream
Number of subjects: 27
Study 31839501 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 27
Study 30833170 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1·0 mg
Number of subjects: 302
Study 30833170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 29096777 — intervention group
Group type: EXPERIMENTAL
Intervention: PedPRM (2 mg escalated to 5 mg)
Number of subjects: 125
Study 29096777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 26296794 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg roflumilast
Number of subjects: 197
Study 26296794 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg roflumilast
Number of subjects: 197
Study 26296794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg roflumilast
Number of subjects: 197
Study 26296794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 23163793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 22
Study 23163793 — intervention group
Group type: COMPARATOR
Intervention: Non-Mediterranean diet (non-MD)
Number of subjects: 22
Study 21777019 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS(LTP) - 200 repetitions of TMS pulses paired with median nerve electrical stimulation at ISI equal to individual latencies of evoked response of somatosensory cortex (N(20)).
Number of subjects: 0
Study 21777019 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS(LTD) - 200 repetitions of TMS pulses paired with median nerve electrical stimulation at ISI of N(20) shortened for 5 msec.
Number of subjects: 0
Study 19563187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation and oral administration of placebo
Number of subjects: 250
Study 19563187 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Mosapride citrate dispersible tablets, Domperidone, and Omeprazole with placebo treatment of transcutaneous electrical acupoint stimulation
Number of subjects: 250
Study 16719611 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher trait anxiety
Number of subjects: 86
Study 16719611 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater asthma severity
Number of subjects: 86
Study 15079110 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty
Number of subjects: 0
Study 15079110 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 0
Study 11240871 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg.kg‐1
Number of subjects: 45
Study 11240871 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg.kg‐1
Number of subjects: 45
Study 11240871 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg.kg‐1 plus Metoclopramide 0.2 mg.kg‐1
Number of subjects: 45
Study 9372483 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX)
Number of subjects: 16
Study 9372483 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NOE)
Number of subjects: 16
Study 9372483 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal plantar flexor EMG
Number of subjects: 16
Study 8514073 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 122
Study 8514073 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 122
Study 3797469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium levels 0.46‐0.60 mEq/l (group B)
Number of subjects: 4
Study 3797469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium levels 0.61‐0.75 mEq/l (group C)
Number of subjects: 4
Study 3797469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium levels 0.76‐0.90 mEq/l (group D)
Number of subjects: 4
Study 3797469 — intervention group
Group type: COMPARATOR
Intervention: Lithium levels 0.30‐0.45 mEq/l (group A)
Number of subjects: 4
Study 3797469 — intervention group
Group type: COMPARATOR
Intervention: All groups compared to group A
Number of subjects: 4
Study 31751547 — intervention group
Group type: EXPERIMENTAL
Intervention: Current epilepsy treatments
Number of subjects: 0
Study 31751547 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision medicine for improved seizure control and reduced toxicity
Number of subjects: 0
Study 31751547 — intervention group
Group type: EXPERIMENTAL
Intervention: Advances from genomic sequencing techniques
Number of subjects: 0
Study 31751547 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of potential new therapeutic targets
Number of subjects: 0
Study 29681046 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1 g/day orally for two months
Number of subjects: 84
Study 29681046 — intervention group
Group type: COMPARATOR
Intervention: Non-receiving (control)
Number of subjects: 84
Study 29681046 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine treatment
Number of subjects: 84
Study 27895846 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2767
Study 27895846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 2767
Study 27895846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2767
Study 24115337 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with T1D >2 years
Number of subjects: 92
Study 24115337 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with T1D <1 year
Number of subjects: 92
Study 24115337 — intervention group
Group type: COMPARATOR
Intervention: Historical non-diabetic controls
Number of subjects: 92
Study 23696104 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of integrative body-mind training (IBMT)
Number of subjects: 34
Study 23696104 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 34
Study 22050795 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase (propofol anesthesia at 1.5-2.0 μg/mL)
Number of subjects: 12
Study 22050795 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-late luteal phase (propofol anesthesia at 1.5-2.0 μg/mL)
Number of subjects: 12
Study 22050795 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ΔP(CRIT) between phases
Number of subjects: 12
Study 22050795 — intervention group
Group type: COMPARATOR
Intervention: R(US) measurements
Number of subjects: 12
Study 18838589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir plus raltegravir (400 mg raltegravir; 100 mg ritonavir every 12 h for 16 days with 400 mg raltegravir on day 14)
Number of subjects: 0
Study 18838589 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz plus raltegravir (400 mg raltegravir; 600 mg efavirenz once daily for 14 days with 400 mg raltegravir on day 12)
Number of subjects: 0
Study 17153880 — intervention group
Group type: EXPERIMENTAL
Intervention: 75000 SQ-T units
Number of subjects: 43
Study 17153880 — intervention group
Group type: EXPERIMENTAL
Intervention: 150000 SQ-T units
Number of subjects: 43
Study 17153880 — intervention group
Group type: EXPERIMENTAL
Intervention: 300000 SQ-T units
Number of subjects: 43
Study 17153880 — intervention group
Group type: EXPERIMENTAL
Intervention: 500000 SQ-T units
Number of subjects: 43
Study 17153880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12409281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 12
Study 12409281 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 12
Study 11022421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (R)
Number of subjects: 124
Study 11022421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 124
Study 11022421 — intervention group
Group type: EXPERIMENTAL
Intervention: Caposide-50 (C-50)
Number of subjects: 124
Study 11022421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cintome (Ci)
Number of subjects: 124
Study 11022421 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetene (A)
Number of subjects: 124
Study 11022421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cozaar (Co)
Number of subjects: 124
Study 11022421 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 124
Study 8865280 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 28
Study 8865280 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA Super Preemie formula
Number of subjects: 28
Study 8865280 — intervention group
Group type: EXPERIMENTAL
Intervention: Similac, Special Care formula
Number of subjects: 28
Study 1800454 — intervention group
Group type: COMPARATOR
Intervention: Double blind placebo controlled clinical trial
Number of subjects: 81
Study 6213380 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5 percent
Number of subjects: 39
Study 6213380 — intervention group
Group type: COMPARATOR
Intervention: Topical benzoyl peroxide 5 percent in 8 percent urea
Number of subjects: 39
Study 31910989 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching operations
Number of subjects: 4560
Study 31910989 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior surgeons
Number of subjects: 4560
Study 31910989 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical experience
Number of subjects: 4560
Study 31910989 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures of shorter and medium duration
Number of subjects: 4560
Study 30298625 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised aerobic exercise training (EX)
Number of subjects: 12
Study 30298625 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 12
Study 27795558 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 1583
Study 27795558 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/m2 Gemtuzumab ozogamicin (GO)
Number of subjects: 1583
Study 27795558 — intervention group
Group type: COMPARATOR
Intervention: No Gemtuzumab ozogamicin (GO)
Number of subjects: 1583
Study 25792557 — intervention group
Group type: EXPERIMENTAL
Intervention: Home aerobic exercise training (EX) consisting of 8 weeks of home walking for 1 hour/day, 5 days/week at 60% to 80% of heart rate reserve, followed by 16 weeks of maintenance home walking for 150 min/week.
Number of subjects: 160
Study 25792557 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) with no exercise directives, monitored by monthly telephone contact.
Number of subjects: 160
Study 24461523 — intervention group
Group type: EXPERIMENTAL
Intervention: P. niruri infusion (5 g/750 mL)
Number of subjects: 5
Study 24461523 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 5
Study 22935645 — intervention group
Group type: EXPERIMENTAL
Intervention: Biased information pamphlet
Number of subjects: 216
Study 22935645 — intervention group
Group type: COMPARATOR
Intervention: Neutral information pamphlet
Number of subjects: 216
Study 22935645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (biased and neutral)
Number of subjects: 216
Study 20095496 — intervention group
Group type: EXPERIMENTAL
Intervention: W‐F168‐B dialyzer reprocessing machine
Number of subjects: 0
Study 20095496 — intervention group
Group type: COMPARATOR
Intervention: RENATRON II dialyzer reprocessing machine
Number of subjects: 0
Study 17824581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.04%
Number of subjects: 0
Study 17824581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.1%
Number of subjects: 0